Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2018

Rutherford SC, Stewart EN, Chen Z, Chadburn A, Wehrli NE, Van Besien K, et al. The eIF4E inhibitor ribavirin as a potential antilymphoma therapeutic: early clinical data^. Leuk Lymphoma. 2018;59(1):256-258.

Stopsack KH, Gonzalez-Feliciano AG, Peisch SF, Downer MK, Gage RA, Finn S, et al. A Prospective Study of Aspirin Use and Prostate Cancer Risk by Status. Cancer Epidemiol Biomarkers Prev. 2018;27(10):1231-1233.

Vaisitti T, Braggio E, Allan JN, Arruga F, Serra S, Zamò A, et al. Novel Richter Syndrome Xenograft Models to Study Genetic Architecture, Biology, and Therapy Responses. Cancer Res. 2018;78(13):3413-3420.

Ahearn TU, Peisch S, Pettersson A, Ebot EM, Zhou CK, Graff RE, et al. Expression of IGF/insulin receptor in prostate cancer tissue and progression to lethal disease. Carcinogenesis. 2018;39(12):1431-1437.

Avecilla ST, Goss C, Marionneaux SM, Wright DR, Leiva TD, Tonon J-, et al. Method comparison study of peripheral blood CD34+ count performed on an Abbott CELL-DYN Sapphire hematology analyzer versus flow cytometry reference procedure (modified ISHAGE). Adv Cell Gene Ther. 2018;1(2).

Huang J, Diaz-Meco MT, Moscat J. The macroenviromental control of cancer metabolism by p62. Cell Cycle. 2018;17(17):2110-2121.

Reich-Slotky R, Makhani SS, Vasovic LV, Pearse RN, Rossi A, Philips A, et al. Comparison of time to engraftment between autologous patients receiving washed versus non-washed cryopreserved peripheral blood stem cell products. Leuk Lymphoma. 2018;59(12):2829-2835.

Kyriakides PW, Inghirami G. Are we ready to take full advantage of patient-derived tumor xenograft models? Hematol Oncol. 2018;36(1):24-27.

Saab J, Santos-Zabala ML, Loda M, Stack EC, Hollmann TJ. Fatty Acid Synthase and Acetyl-CoA Carboxylase Are Expressed in Nodal Metastatic Melanoma But Not in Benign Intracapsular Nodal Nevi. Am J Dermatopathol. 2018;40(4):259-264.

Hsu JM, Artz A, Mayer SA, Guarner D, Bishop MR, Reich-Slotky R, et al. Combined Haploidentical and Umbilical Cord Blood Allogeneic Stem Cell Transplantation for High-Risk Lymphoma and Chronic Lymphoblastic Leukemia. Biol Blood Marrow Transplant. 2018;24(2):359-365.